Bayer AG: Market Performance Snapshot
Bayer AG (ticker BAYN.DE) closed the 24‑hour trading window at EUR 43.98, reflecting a +2.64 % gain from the previous close. The stock traded on the Xetra exchange, with a current trading volume of EUR 103.4 million over the last day.
| Metric | Value |
|---|---|
| Shares Outstanding | 982.4 million |
| Market Capitalisation | EUR 47.7 bn |
| Current Price | EUR 43.98 |
| Price‑to‑Earnings Ratio | 12.35 (derived from market data) |
| Simple Moving Average (200 days) | EUR 43.42 |
| 52‑Week High | EUR 53.92 (07/03/2026) |
| 52‑Week Low | EUR 25.78 (11/07/2025) |
Recent Trend
- Month‑to‑Date Performance: The stock is down –9.93 % since the end of the last month, indicating a broader corrective trend that is now showing signs of reversal.
- Volume Context: Trading activity of EUR 103.4 million suggests healthy liquidity, while the price movement aligns with a moderate bullish phase relative to the 200‑day average.
Comparative Peer Analysis (24 H)
| Peer | Ticker | % Move | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Mercedes‑Benz | MBG.DE | –0.77 % | EUR 40.74 | EUR 44.4 bn | 7.83 |
| Deutsche Börse | DB1.DE | –0.29 % | EUR 314.1 | EUR 56.8 bn | 25.44 |
| Volkswagen | VOW.DE | –0.93 % | EUR 68.7 | EUR 37.7 bn | 6.62 |
| BASF | BAS.DE | –0.10 % | EUR 52.45 | EUR 51 bn | 22.11 |
| Siemens Healthineers | SHL.DE | +0.65 % | EUR 41.86 | EUR 46.7 bn | 21.11 |
Bayer’s performance outpaces its automotive and industrial peers, which have largely trended downward, and aligns more closely with the up‑momentum seen in Siemens Healthineers. This differential suggests that Bayer’s underlying fundamentals—particularly its diversified healthcare and agro‑chemical portfolio—continue to command investor confidence.
Strategic Outlook
Bayer’s product pipeline spans a broad spectrum of high‑margin therapeutic areas, from oncology to cardiovascular care, alongside a robust portfolio of crop‑protection and specialty chemical solutions. The company’s recent earnings disclosures have underscored steady revenue growth and improving gross margins, positioning it well to weather macro‑economic headwinds. With a solid balance sheet and ongoing R&D investments, Bayer is poised to capitalize on emerging opportunities in both developed and emerging markets.
Investors should monitor the company’s quarterly guidance and any regulatory developments that could impact its drug approvals or commodity pricing. The current price level sits slightly above the 200‑day moving average, offering a potential entry point for medium‑term investors seeking exposure to a well‑diversified, global healthcare and chemical producer.
For further details on Bayer AG’s operations and corporate strategy, please visit the official website at www.bayer.com .
